Hemab Therapeutics

Public

Copenhagen, Capital Region of DenmarkBiotechhttps://www.hemab.com/

Hemab Therapeutics is now publicly traded

The data on this page reflects Hemab Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

May 4, 2026

Last Round

Series C

Oct 27, 2025

Total Funding Raised

$853.66M

Company Overview

Hemab Therapeutics is a biotechnology company that develops prophylactic therapeutics aimed at treating bleeding and thrombosis disorders by enhancing the body's natural clotting mechanisms to prevent life-threatening complications.

Sector

Biotech

Verticals

Digital Health, HealthTech, Life Sciences

AI Layer

Non-AI

Keywords

biotechnologymonoclonal antibodybleeding disordersrare diseaseclinical-stage biotechbispecific antibodyGlanzmann Thrombastheniablood coagulationprophylactic therapeuticsclinical trialsdrug developmentorphan drugbiopharmahematologypipeline assets

Hemab Therapeutics Comparables

Compare Hemab Therapeutics with similar companies based on industry and business-model similarity.

Hemab Therapeutics comparables — related companies by embedding similarity
Company	Similarity	Market Cap
Star Therapeutics	79%	Book a demo
Eli Lilly and Company	77%	Book a demo
Incyte Corporation	73%	Book a demo

Book a demo to see all comparables

For institutional investors. Book with your work email.

Hemab Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
IPO	May 4, 2026	Book a demo	Book a demo	Book a demo	Book a demo
Series C	Oct 27, 2025	Book a demo	Book a demo	Book a demo	Book a demo
Series C	Oct 27, 2023	Book a demo	Book a demo	Book a demo	Book a demo
Series B	Feb 16, 2023	Book a demo	Book a demo	Book a demo	Book a demo
Series A	Jul 22, 2021	Book a demo	Book a demo	Book a demo	Book a demo
Seed	Dec 14, 2020	Book a demo	Book a demo	Book a demo	Book a demo

Book a demo to see all 6 rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Benny Sorensen

Chief Executive Officer

Executive Team

Mads Behrndt

Chief Financial Officer

Executive Team

For institutional investors. Book with your work email.

Hemab Therapeutics Investors

Notable investors and investment history

Hemab Therapeutics investors
Investor	Rounds
Jefferies	IPO
Access Industries	Series B
Evercore ISI	IPO
Maj Invest Equity A/S	Series B, Series C
RA Capital Management	Series C, Series B, Series A
Avoro Ventures	Series C, Series B
Avoro Capital	Series B

Book a demo to see all investors

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

attends_eventNov 4, 2026
Hemab presents clinical and preclinical data from multiple blood coagulation programs at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition in Louisiana and virtually in Dec '26.
has_valuationOct 8, 2026
On Oct 8th '26, Hemab's shares rise 6% to about $30.43, giving the company an approximately $1.41B market capitalization.
is_developingSep 24, 2026
As of Sep 24th '26, Hemab is developing a franchise of innovative therapeutics to address critical gaps in coagulation-disorder treatment, including sutacimig (HMB-001), HMB-002, and HMB-003, all in clinical development for prophylactic or heavy-menstrual-bleeding indications.
is_developingSep 24, 2026
On Oct 8th '26, Hemab is developing HMB-001, an investigational treatment for serious bleeding disorders.
hiresSep 24, 2026
Hemab appoints Keli Walbert to its Board of Directors, effective Sep 24th '26 in Massachusetts and Denmark, with Walbert joining the Audit Committee.